218 related articles for article (PubMed ID: 31190905)
41. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
42. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.
Webb BJ; Harrington R; Schwartz J; Kammerer J; Spalding J; Lee E; Dodds B; Kaufusi S; Goodman BE; Firth SD; Martin G; Sorensen J; Hoda D
Transpl Infect Dis; 2018 Oct; 20(5):e12961. PubMed ID: 29975816
[TBL] [Abstract][Full Text] [Related]
43. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
44. Letermovir: First Global Approval.
Kim ES
Drugs; 2018 Jan; 78(1):147-152. PubMed ID: 29288370
[TBL] [Abstract][Full Text] [Related]
45. Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation.
Li PH; Lin CH; Lin YH; Chen TC; Hsu CY; Teng CJ
Ther Adv Hematol; 2021; 12():2040620721998124. PubMed ID: 33747424
[TBL] [Abstract][Full Text] [Related]
46. Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults.
Politikos I; Lau C; Devlin SM; Quach S; Lin A; Perales MA; Shah GL; Seo SK; Papanicolaou GA; Barker JN
Blood Adv; 2022 Dec; 6(24):6291-6300. PubMed ID: 35802462
[TBL] [Abstract][Full Text] [Related]
47. [Management of cytomegalovirus infection after hematopoietic stem cell transplantation].
Mori T
Rinsho Ketsueki; 2019; 60(9):1337-1340. PubMed ID: 31597861
[TBL] [Abstract][Full Text] [Related]
48. A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation.
Tilden DP; Chapman J; Davey PJ; Solly ML; Crowley S
Clin Transplant; 2004 Jun; 18(3):312-20. PubMed ID: 15142054
[TBL] [Abstract][Full Text] [Related]
49. Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience.
Martino M; Pitino A; Gori M; Bruno B; Crescimanno A; Federico V; Picardi A; Tringali S; Ingrosso C; Carluccio P; Pastore D; Musuraca G; Paviglianiti A; Vacca A; Serio B; Storti G; Mordini N; Leotta S; Cimminiello M; Prezioso L; Loteta B; Ferreri A; Colasante F; Merla E; Giaccone L; Busca A; Musso M; Scalone R; Di Renzo N; Marotta S; Mazza P; Musto P; Attolico I; Selleri C; Canale FA; Pugliese M; Tripepi G; Porto G; Martinelli G; Carella AM; Cerchione C
Front Oncol; 2021; 11():740079. PubMed ID: 34616684
[TBL] [Abstract][Full Text] [Related]
50. Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant.
Shigle TL; Handy VW; Chemaly RF
Ther Adv Hematol; 2020; 11():2040620720937150. PubMed ID: 32637057
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.
Mauskopf JA; Richter A; Annemans L; Maclaine G
Pharmacoeconomics; 2000 Sep; 18(3):239-51. PubMed ID: 11147391
[TBL] [Abstract][Full Text] [Related]
52. In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products.
Komatsu TE; Hodowanec AC; Colberg-Poley AM; Pikis A; Singer ME; O'Rear JJ; Donaldson EF
Antiviral Res; 2019 Sep; 169():104549. PubMed ID: 31279814
[TBL] [Abstract][Full Text] [Related]
53. Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation.
Daniels K; Clemmons A
J Adv Pract Oncol; 2019; 10(7):730-735. PubMed ID: 33391856
[TBL] [Abstract][Full Text] [Related]
54. The cost-effectiveness of preventing AIDS-related opportunistic infections.
Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
[TBL] [Abstract][Full Text] [Related]
55. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
56. Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies.
Vyas A; Raval AD; Kamat S; LaPlante K; Tang Y; Chemaly RF
Open Forum Infect Dis; 2023 Jan; 10(1):ofac687. PubMed ID: 36726548
[TBL] [Abstract][Full Text] [Related]
57. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
58. CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients.
Chavaz L; Royston L; Masouridi-Levrat S; Mamez AC; Giannotti F; Morin S; Van Delden C; Chalandon Y; Neofytos D
Open Forum Infect Dis; 2023 Apr; 10(4):ofad169. PubMed ID: 37125233
[TBL] [Abstract][Full Text] [Related]
59. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
